Award winning Chief Executive Officer and Founder of CAVU Biotherapies. CAVU is a revenue-generating, regulatory compliant biotech company with patented platform technology. The company's focus is on manufacturing of cellular immunotherapies and diagnostics for pets with autoimmune diseases and cancer to improve health outcomes and keep pet families together for a longer period of time.Increased survival rate 161% through the safe infusion of the world’s first Autologous T-cell Therapy to treat canine T-cell Lymphoma through the development of innovative manufacturing techniques.Lead the overall strategic and transformative direction, plus short-term projections resulting in additional R&D pipeline species and disease targets to increase total addressable market.Defined a value proposition to support budget and long-range plan development.Oversaw the completion of milestones in R&D, corporate strategy, business development, finances, and operations.Directed negotiations with vendors, government agencies, and customers.Secured investor funding to support a first to market product launch. Drove business model implementation.Implemented unique QMS interface to govern business development, R&D, and operations.Reduced manufacturing time 38% by optimizing production cGMP and GLP SOPs. Achieved 95% patient therapy manufacturing success rate. Reduced COGs 54% by evolving improvement of fundamental operational efficiencies.Executed strategic and potentially lucrative partnerships. Performed competitive analysis and risk management.Developed commercial relationships with 61 veterinary clinics in the US and Canada.Collaborated with the top 5 pet insurance companies to win 100% plan coverage of products. Conveyed scientific materials to deliver information consistent with regulatory guidelines. Built strong brand management and increased sales 11x over previous year.Obtained USDA authorization for immediate commercialization of products and licenses.

Designed, manufactured, and completed translational clinical trials with focus on the development of companion canine comparative oncology model to inform on adoptive Chimeric Antigen Receptor (CAR) CAR+ and CARNEG mRNA transduced T-cell therapy as viable treatment model for human non-Hodgkin’s Lymphoma. Developed the use of genomic T-cell biomarkers to aid in cancer prognosis and quantification of immune health as it relates to cancer. Continued to successfully support advances in canine CAR and TCR T-cell therapy through trials focusing on B-cell Lymphoma diagnosed dogs treated with allogeneic and autologous bone marrow transplants.

Designed and conducted Phase 1 translational clinical trials to develop companion canine comparative oncology model and inform adoptive CAR+ and CARNEG T-cell therapy as viable treatment model for human non-Hodgkin’s Lymphoma.• Designed protocols and conducted translational clinical trials to study adoptive CAR+ and CARNEG T-cell therapy for human non-Hodgkin’s Lymphoma, Acute Myeloind Leukemia, Osteosarcoma, and Glioblastoma.• Successfully performed world's first adoptive T-cell therapy infusion into a pet dog. • Utilized hybridomas to develop anti-canine tumor antigen antibody to develop novel CAR sequences. • Developed and optimized novel platform technologies that positively impacted the treatment of canine and human lymphoma. • Spearheaded a fruitful and collaborative relationship with academic institutions like Texas A&M University College of Veterinary Medicine as well as private national and international veterinarian practices.

Conducted husbandry and research on non-venomous, poisonous marine, freshwater animals, penguins, sharks, stingrays, reptiles, amphibians, jellyfish/corals, and other invertebrates. Directed and organized Small Tank Veterinary Quarantine Facilities.